Lenalidomide Plus Dexamethasone as FIRST-Line Therapy in Transplant-Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non-Interventional Study FIRST-NIS and Comparison With
19 hours ago
- #Multiple Myeloma
- #Real-World Evidence
- #Geriatric Oncology
- The FIRST-NIS study evaluated lenalidomide plus low-dose dexamethasone (Rd) as first-line therapy in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients in a real-world German setting.
- With a median follow-up of 64.2 months, median progression-free survival was 22.9 months and median overall survival was 58.1 months, showing effectiveness comparable to the pivotal FIRST phase III trial.
- Rd maintained quality of life, was feasible in patients with renal impairment, and had no new safety signals, supporting its use as a frontline treatment regardless of age.